Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients

L. Boekel; G. J. Wolbink

doi:10.1016/S2665-9913(21)00418-5

Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Original language	English
Pages (from-to)	e154-e155
Journal	The Lancet Rheumatology
Volume	4
Issue number	3
DOIs	https://doi.org/10.1016/S2665-9913(21)00418-5
Publication status	Published - 1 Mar 2022

Access to Document

10.1016/S2665-9913(21)00418-5

Cite this

@article{688803a6da2148edb625e372a5ba4627,

title = "Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients",

author = "L. Boekel and Wolbink, {G. J.}",

note = "Funding Information: GJW received funding from ZonMw for COVID-19 research (project number 10430022010020) outside the committed work. LB declares no competing interests.",

year = "2022",

month = mar,

day = "1",

doi = "10.1016/S2665-9913(21)00418-5",

language = "English",

volume = "4",

pages = "e154--e155",

journal = "The Lancet Rheumatology",

issn = "2665-9913",

publisher = "Lancet Publishing Group",

number = "3",

}

TY - JOUR

T1 - Rituximab during the COVID-19 pandemic

T2 - time to discuss treatment options with patients

AU - Boekel, L.

AU - Wolbink, G. J.

N1 - Funding Information: GJW received funding from ZonMw for COVID-19 research (project number 10430022010020) outside the committed work. LB declares no competing interests.

PY - 2022/3/1

Y1 - 2022/3/1

UR - http://www.scopus.com/inward/record.url?scp=85125226230&partnerID=8YFLogxK

U2 - 10.1016/S2665-9913(21)00418-5

DO - 10.1016/S2665-9913(21)00418-5

M3 - Comment/Letter to the editor

C2 - 34977601

SN - 2665-9913

VL - 4

SP - e154-e155

JO - The Lancet Rheumatology

JF - The Lancet Rheumatology

IS - 3

ER -

Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients

Access to Document

Other files and links

Cite this